protocolSection identificationModule nctId: NCT06357455, orgStudyIdInfo id: Platelet CellSaver Liver trnsp, briefTitle: Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery, acronym: PLFLTS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-10, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Eduardo Schiffer, class: OTHER, collaborators name: University Hospital, Geneva, collaborators name: Insel Gruppe AG, University Hospital Bern, descriptionModule briefSummary: Intraoperative cell salvage is commonly used in surgeries that carry a major hemorrhagic risk to reduce the administration of allogeneic red blood cells and thus improve the outcome for the patient. When processing the salvaged blood, however, a large part of the patient's plasma is washed out. This is a disadvantage with regard to an optimal coagulation status after these types of surgeries, especially liver transplantation.There are currently various cell saver systems on the market. According to the manufacturers, the plasma is returned to the patient in different quantities as part of the processing procedure. Thus, it can be assumed that in addition to red blood cells, platelets (part of plasma) are re-transfused and contribute to an optimized coagulation. Unfortunately, there is a lack of studies in this regard in the liver transplant surgery population.The investigators aim to study the performance of two different cell saver devices regarding preservation of platelet number and function., conditionsModule conditions: Liver Transplant, conditions: Hemorrhage, Surgical, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Cell Salvage Autotransfusion: SAME™ device, interventions name: Cell Salvage Autotransfusion: Autolog™ device, outcomesModule primaryOutcomes measure: Platelet number, secondaryOutcomes measure: Platelet function, secondaryOutcomes measure: Platelet function, secondaryOutcomes measure: Platelet function, secondaryOutcomes measure: Platelet function, secondaryOutcomes measure: Platelet function, secondaryOutcomes measure: Platelet function, secondaryOutcomes measure: Blood plasma albumin level, secondaryOutcomes measure: Blood hemoglobin level, secondaryOutcomes measure: Blood lactate level, secondaryOutcomes measure: Free hemoglobin level, secondaryOutcomes measure: Anti-Xa activity, secondaryOutcomes measure: Number of allogeneic blood products used, secondaryOutcomes measure: Number of coagulation concentrates used, secondaryOutcomes measure: Amount of autologous blood at the end of the liver transplantation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Geneva University Hospitals, city: Geneva, zip: 1211, country: Switzerland, contacts name: Eduardo Schiffer, MD, role: CONTACT, email: eduardo.schiffer@hcuge.ch, contacts name: Tony Mouawad, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 46.20222, lon: 6.14569, hasResults: False